Last week, Novartis (NYSE: NVS)paid up almost $10 billion for AveXis -- an 88% premium over the gene therapy company's previous close. In this segment from Industry Focus: Healthcare , host Michael Douglass and Motley Fool contributor Shannon Jones explain why Novartis is so interested in this company and why this acquisition is so exciting.
What Novartis Bought in AveXis
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться